| Fruquintinib | 393.399
C21H19N3O5 |  | A VEGF receptor inhibitor used to treat metastatic colorectal cancer. | Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring |
| Daprodustat | 393.44
C19H27N3O6 |  | A small-molecule hypoxia-inducible factor prolyl hydroxylase inhibitor used for the treatment of anemia in patients with chronic kidney disease. | Amino Acids / Amino Acids, Peptides, and Proteins / Antianemic Preparations / BCRP/ABCG2 Substrates / Blood and Blood Forming Organs / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor / Hypoxia-Inducible Factor-Proline Dioxygenases, antagonists & inhibitors / OAT1/SLC22A6 Substrates / OAT3/SLC22A8 Substrates / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / Pyrimidines / Pyrimidinones |
| Selumetinib | 457.68
C17H15BrClFN4O3 |  | A MEK 1/2 inhibitor used in pediatric patients to treat neurofibromatosis type 1 (NF1) accompanied by symptomatic, inoperable plexiform neurofibromas (PN). | Mitogen-activated protein kinase (MEK) inhibitors |
| Naldemedine | 570.646
C32H34N4O6 |  | An opioid antagonist used to to treat opioid-induced constipation. | Peripheral Opioid Receptor Antagonists |
| Voclosporin | 1214.646
C63H111N11O12 |  | A calcineurin inhibitor for the treatment of lupus nephritis (LN) in patients diagnosed with systemic lupus erythematosus (SLE). | Calcineurin Inhibitors |
| Pacritinib | 472.589
C28H32N4O3 |  | A kinase inhibitor used for the treatment of primary and secondary myelofibrosis in adult patients with significantly reduced platelet counts. | Janus Kinase Inhibitor |
| Tropisetron | 284.3529
C17H20N2O2 |  | A 5HT-3 receptor antagonist used as an antiemetic in the treatment of chemotherapy-induced nausea and vomiting. | Serotonin 5-HT3 Receptor Antagonists |
| Setmelanotide | 1117.32
C49H68N18O9S2 |  | Setmelanotide is indicated to treat obesity caused by genetic POMC, PCSK1, or LEPR deficiencies or Bardet-Biedl syndrome. | Centrally Acting Antiobesity Products |
| Acalabrutinib | 465.517
C26H23N7O2 |  | A Bruton tyrosine kinase inhibitor used to treat mantle cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma. | Bruton's tyrosine kinase (BTK) inhibitors / Protein Kinase Inhibitors |
| Iomeprol | 777.089
C17H22I3N3O8 |  | An iodine-based X-ray contrast agent. | Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media |
| Tezacaftor | 520.505
C26H27F3N2O6 |  | A medication used to treat homozygous or heterozygous F508del mutation cystic fibrosis. | BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inducers / Cytochrome P-450 CYP3A5 Inducers (strength unknown) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dioxoles / Heterocyclic Compounds, Fused-Ring / OAT1/SLC22A6 inhibitors / OAT3/SLC22A8 Inhibitors / OATP1B1/SLCO1B1 Inhibitors / OATP1B1/SLCO1B1 Substrates / OATP1B3 inhibitors / OCT2 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates |
| Encorafenib | 540.01
C22H27ClFN7O4S |  | A kinase inhibitor used to treat unresectable or metastatic melanoma with specific mutations. | B-Raf serine-threonine kinase (BRAF) inhibitors / Protein Kinase Inhibitors |
| Ribociclib | 434.548
C23H30N8O |  | A kinase inhibitor used to treat HR+, HER2- advanced or metastatic breast cancer. | Cyclin-dependent kinase (CDK) inhibitors / Protein Kinase Inhibitors |
| Lasmiditan | 377.367
C19H18F3N3O2 |  | An oral 5HT1F agonist used for the acute treatment of migraine headache with or without aura. | Amides / Analgesics / Antidepressive Agents / Antimigraine Preparations / BCRP/ABCG2 Inhibitors / Central Nervous System Depressants / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inhibitors / MATE 1 Inhibitors / MATE 2 Inhibitors / MATE inhibitors / Nervous System / Neurotransmitter Agents / OCT1 inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome / Serotonin (5-HT) 1F Receptor Agonists / Serotonin Agents |
| Galactose | 180.1559
C6H12O6 |  | There are limited therapeutic uses for which galactose is formally indicated. Some predominant indications include (a) the use of galactose to facilitate the construction of structurally and immunologically effective attenuated... | Tests for Liver Functional Capacity |
| Rilmenidine | 180.251
C10H16N2O |  | An I1-imidazoline receptor agonist used to treat hypertension. | Imidazoline Receptor Agonists |
| Vonoprazan | 345.39
C17H16FN3O2S |  | A potassium-competitive acid blocker used in the treatment of acid-related disorders and as an adjunct to Helicobacter pylori eradication. | Alimentary Tract and Metabolism / Amides / Cytochrome P-450 CYP2B6 Substrates / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP2D6 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs for Acid Related Disorders / Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord) / Gastric Acid Lowering Agents / P-glycoprotein inhibitors / Potassium-competitive Acid Blockers / Sulfones / Sulfur Compounds |
| Ebastine | 469.6576
C32H39NO2 |  | A second generation H1-receptor antagonist useful in the treatment of allergic rhinitis and urticaria. | Histamine H1 Antagonists |
| Benfotiamine | 466.45
C19H23N4O6PS |  | A derivative of thiamine thought to be useful in the management of diabetic neuropathy, although evidence is lacking. | Vitamin B Complex |
| Clobetasol | 410.907
C22H28ClFO4 |  | Clobetasol is under investigation for the treatment of Scleroderma. Clobetasol has been investigated for the prevention of Psoriasis and Cutaneous Atrophy Due to Corticosteroids. | Corticosteroids, Very Potent (Group IV) |
| Cabotegravir | 405.358
C19H17F2N3O5 |  | An HIV-1 integrase inhibitor used for treatment and pre-exposure prophylaxis of HIV-1 infection. | HIV Integrase Inhibitors / Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor |
| Rifamycin | 697.778
C37H47NO12 |  | An antibacterial used to treat traveler's diarrhea. | Anti-Bacterial Agents |
| Istradefylline | 384.436
C20H24N4O4 |  | A selective adenoside A2A receptor antagonist indicated in adjunct to levodopa and carbidopa for the treatment of Parkinson's Disease. | Adenosine A2 Receptor Antagonists |
| Talazoparib | 380.359
C19H14F2N6O |  | A poly-ADP ribose polymerase inhibitor used to treat HER2-, BRCA mutated locally advanced or metastatic breast cancer and HRR gene-mutated metastatic castration-resistant prostate cancer. | Poly (ADP-ribose) polymerase (PARP) inhibitors |
| Tenapanor | 1145.04
C50H66Cl4N8O10S2 |  | An NHE3 inhibitor indicated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic kidney disease, | Alimentary Tract and Metabolism / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Substrates / Drugs for Constipation / Heterocyclic Compounds, Fused-Ring / Organic Anion Transporting Polypeptide 2B1 Inhibitors / Sodium-Hydrogen Exchanger 3 Inhibitor / Sodium/Hydrogen Exchanger 3 (NHE3) Inhibitors / Sulfur Compounds |
